ArticleMaterials today. Bio2026
Biomimetic dual-driven STING nanoagonist orchestrates neoadjuvant mild photo-immunotherapy for fibrosarcoma.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrosarcoma is an infiltrative malignant soft tissue sarcoma primarily managed with extensive surgical resection. However, securing adequate margins often compromises organ function, while postoperative recurrence and distant metastasis remain formidable clinical challenges, underscoring the urgent need for effective neoadjuvant therapeutic strategies. Neoadjuvant mild photo-immunotherapy represents a promising strategy for coupling preoperative tumor shrinkage with systemic immune priming. Notably, integrated analyses revealed relatively high expression of stimulator of interferon genes (STING) in fibrosarcoma, highlighting STING as a rational target for immunomodulation. Herein, we developed a biomimetic dual-driven STING nanoagonist for neoadjuvant mild photo-immunotherapy against fibrosarcoma. This nanoagonist comprises poly(lactic-co-glycolic acid) (PLGA) nanoparticles co-encapsulating the STING agonist 2',3'-cyclic GMP-AMP (cGAMP) and the photosensitizer indocyanine green (ICG) (cGAMP/ICG@PLGA, GIP), which are further camouflaged with calreticulin (CRT)-enriched fibrosarcoma cell membranes (CRTM) to form GIP@CRTM. The biomimetic CRTM cloak retains tumor cell membrane antigens and CRT "eat-me" signals, promoting homotypic tumor accumulation and uptake by dendritic cells (DCs), thereby facilitating cGAMP delivery and dual-driven STING activation in both tumor cells and DCs. Upon near-infrared irradiation, ICG-mediated mild phototherapy induces moderate photothermal heating and reactive oxygen species (ROS) generation, triggering immunogenic cell death and further amplifying tumor-intrinsic STING signaling through ROS-induced DNA damage. This synergistic therapeutic effect enabled effective preoperative tumor shrinkage while eliciting systemic antitumor immunity to suppress postoperative contralateral rechallenge tumor outgrowth and limit distant tumor progression. Thus, this study establishes a STING-amplified mild photo-immunotherapeutic strategy, providing a potential neoadjuvant treatment option for fibrosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.